GAS5 silencing induces resistance to, and ectopic GAS5 expression confers sensitivity to, the cytostatic effects of mTOR inhibitors, thereby demonstrating a role for GAS5 lncRNA in mTOR inhibitor action in prostate cancer [46]. The gene discussed is MTOR; the disease is prostate carcinoma.